Bisoprolol fumarate is a Small Molecule owned by Merck, and is involved in 13 clinical trials, of which 12 were completed, and 1 is ongoing.
Bisoprolol is a cardioselective beta-1 adrenergic receptor antagonist with antihypertensive and potential cardioprotective activities. Bisoprolol selectively and competitively binds to and blocks beta-1 adrenergic receptors in the heart, decreasing cardiac contractility and rate, reducing cardiac output, and lowering blood pressure. In addition, it may exhibit antihypertensive activity through the inhibition of renin secretion by juxtaglomerular epithelioid (JGE) cells in the kidney, thus inhibiting activation of the renin-angiotensin system (RAS).
The revenue for Bisoprolol fumarate is expected to reach a total of $13.4bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Bisoprolol fumarate NPV Report.
Bisoprolol fumarate is currently owned by Merck.
Bisoprolol fumarate Overview
Bisoprolol fumarate (Cardicor/ Concor/ Emconcor/ Detensiel/ Pluscor/ Congescor/ Concor Cor/ Cardensiel/ Emcor LS/ Biselect/ Betacor) is a benzylether derivative, acts as an anti-hypertensive agent. It is formulated as film coated tablets and tablets for oral administration. It is indicated in the treatment of stable chronic heart failure with reduced left ventricular systolic function, hypertension, heart pain due to circulatory disorders in the coronary arteries (coronary heart disease, angina pectoris) and it is indicated for the management of mild to moderate essential hypertension and angina pectoris.
Merck, a subsidiary of E. Merck KG, is a science and technology company. It discovers, develops and manufactures prescription drugs to treat cancer, multiple sclerosis and infertility; and develops liquid crystal mixtures, organic light-emitting diode (OLED) materials, cosmetic active ingredients, pigments for coatings, and high-tech materials. Merck also provides a wide range of products including lab water systems, gene editing tools, cell lines, antibodies and end-to-end systems. The company serves healthcare, performance materials, and life sciences markets. It has presence in Europe, North America, Asia-Pacific, Latin America and Middle East and Africa. Merck is headquartered in Darmstadt, Hesse, Germany.
The company reported revenues of (Euro) EUR19,687 million for the fiscal year ended December 2021 (FY2021), an increase of 12.3% over FY2020. In FY2021, the company’s operating margin was 21.2%, compared to an operating margin of 17% in FY2020. In FY2021, the company recorded a net margin of 15.5%, compared to a net margin of 11.3% in FY2020. The company reported revenues of EUR5,806 million for the third quarter ended September 2022, an increase of 4.3% over the previous quarter.
Quick View – Bisoprolol fumarate
|Highest Development Stage|